IOVA250117P14000
- 7.90
- 0.000.00%
Iovance Biotherapeutics Newsroom
Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA) and Madrigal Pharmaceuticals (MDGL)
Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $25
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $22
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
Iovance Biotherapeutics (IOVA) Gets a Buy From Truist Financial
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)
Iovance Biotherapeutics Shares Are Falling Today: What's Going On?
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Profit Outlook
10 Health Care Stocks With Whale Alerts In Today's Session
Express News | Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
After a Year of 0.6% Returns, Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price Drop Last Week May Have Less of an Impact on Institutional Investors
Peering Into Iovance Biotherapeutics's Recent Short Interest
Is Iovance Biotherapeutics Stock a Millionaire Maker?